Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Donanemab
***
***
The FDA just approved Eli Lilly’s new drug donanemab signing off on the treatment after previous delays. Estimated cost $32-k/year.
CITE: https://www.r2library.com/Resource
The approval expands the limited treatment options for Alzheimer’s as the drug, which will be sold as Kisunla and priced at about ~$32,000 for a year’s supply, will compete with a similar one from Biogen and Eisai that was approved last year. Both drugs target plaques in the brain called amyloids to slow the progression of the disease, representing a breakthrough after decades of failures to find new treatments.
COMMENTS APPRECIATED
Thank You
***
Share this:
Filed under: "Doctors Only", Alerts Sign-Up, Drugs and Pharma, Ethics, Health Economics, Health Insurance | Tagged: Alzheimer, Biogen, Donanemab, Eisai, Kisunla |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a comment